MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome

British Journal of Cancer

Volumn 103, Issue 6, 2010, Pages 820-826

  Hassel, J C ^a   Sucker, A ^a,g   Edler, L ^b   Kurzen, H ^a   Moll, I ^a,g   Stresemann, C ^b,h   Spieth, K ^c   Mauch, C ^d   Rass, K ^e   Dummer, R ^f   Schadendorf, D ^a,g  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h BAYER PHARMA AG   (Germany)

Author keywords

gene methylation; melanoma; MGMT; temozolomide; therapy toxicity

Indexed keywords

ALPHA2B INTERFERON; GENOMIC DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PEGINTERFERON ALPHA2B; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PRIMER DNA; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CORRELATION ANALYSIS; CPG ISLAND; DNA METHYLATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; GENETICS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NUCLEOTIDE SEQUENCE;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA PRIMERS; DNA REPAIR ENZYMES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; PROMOTER REGIONS, GENETIC; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 77956432698     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605796     Document Type: Article

References (23)

1. 6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolo-mide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 9: 1461-1468
2. Debniak T, Scott RJ, Gorski B, Cybulski C, van de Wetering T, Serrano-Fernandez P, Huzarski T, Byrski T, Nagay L, Debniak B, Kowalska E, Jakubowska A, Gronwald J, Wokolorczyk D, Maleszka R, strok;adny J, Lubinski J (2008) Common variants of DNA repair genes and malignant melanoma. Eur J Cancer 44: 110-114
3. Diggle PJ, Liang KY, Zeger SL (1994) Analysis of longitudinal data. Oxford Sci Press: Oxford
4. Dummer R, Hauschild A, Jost L (2008) Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis treatment and follow-up. Ann Oncol 19(Suppl2): ii86-ii88
5. 6 alkylguanine-DNA alkyltransfer-ase activity in human myeloid cells. J Clin Invest 76: 2106-2114
6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med 352: 997-1003
7. Kaina B, Christmann M, Naumann S, Roos WP (2007) MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair 6: 1079-1099
8. Kaufmann R, Spieth K, Leiter U, Mauch C, von den Driesch P, Vogt T, Linse R, Tilgen W, Schadendorf D, Becker JC, Sebastian G, Krengel S, Kretschmer L, Garbe C, Dummer R (2005) Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastastic melanoma: a randomized, phase III, multicenter study from the dermatologic Cooperative Oncology Group. J Clin Oncol 23: 9001-9007
9. Kohonen-Corish MR, Cooper WA, Saab J, Thompson JF, Trent RJ, Millward MJ (2006) Promoter hypermethylation of the O(6)-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma. J Invest Dermatol 126: 167-171
10. 6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br J Cancer 89: 1517-1523
11. Meyer T, Merkel S, Goehl J, Hohenberger W (2000) Surgical therapy for distant metastases of malignant melanoma. Cancer 89: 1983-1991
12. Mhaidat NM, Zhang XD, Allen J, Avery-Kiejda KA, Scott RJ, Hersey P (2007) Temozolomide induces senescence but not apoptosis in human melanoma cells. Br J Cancer 97: 1225-1233
13. 6-methylguanine-DNA methyltrans-ferase in pre-treatment tumor biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 79: 1199-1202
14. Ramirez JL, Taron M, Balana C, Roussos Y, Ariza A, Ballester R, Sarries C, Mendez P, Sanchez JJ, Rosell R (2003) Serum DNA as a tool for cancer patient management. Rocz Akad Med Bialymst 48: 34-41
15. Ranson M, Hersey P, Thompson D, Beith J, McArthur GA, Haydon A, Davis ID, Kefford RF, Mortimer P, Harris PA, Baka S, Seebaran A, Sabharwal A, Watson AJ, Margison GP, Middleton MR (2007) Randomized trial of the combination of lomeguatrib and temozolomide compared with temozo-lomide alone in chemotherapy nä?ve patients with metastatic cutaneous melanoma. J Clin Oncol 25: 2540-2545
16. Rass K, Hassel JC (2009) Chemotherapeutics, chemoresistance and the management of melanoma. G Ital Dermatol Venereol 144: 61-78
17. Rastetter M, Schagdarsurengin U, Lahtz C, Fiedler E, Marsch WCh, Dammann R, Helmbold P (2007) Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma. Histol Histo-pathol 22: 1005-1015
18. Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth AA, Busam K, Smith K, Orlow I, Panageas K, Chapman PB (2008) Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 26: 2299-2304
19. 6-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. DNA Repair 8: 72-86
20. Spieth K, Kaufmann R, Dummer R, Garbe C, Becker JC, Hauschild A, Tilgen W, Ugurel S, Beyeler M, Bröcker EB, Kaehler KC, Pföhler C, Gille J, Leiter U, Schadendorf D (2008) Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Ann Oncol 19: 801-806
21. Tawbi HA, Kirkwood JM (2007) Management of metastatic melanoma. Semin Oncol 34: 532-545
22. Wood TF, DiFronzo A, Rose DM, Haigh PI, Stern SL, Wanek L, Essner R, Morton DL (2001) Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann Surg Oncol 8: 658-662
23. Xiong Z, Laird PW (1997) COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25: 2532-2534